

BIOCRYST PHARMACEUTICALS INC  
Form 8-K  
November 10, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): August 18, 2008**

**BioCryst Pharmaceuticals, Inc.**  
(Exact name of registrant as specified in its charter)

<b>DELAWARE</b> (State or other Jurisdiction of Incorporation)	<b>000-23186</b> (Commission File Number)	<b>62-1413174</b> (IRS Employer Identification No.)
--	--	--

<b>2190 Parkway Lake Drive, Birmingham, Alabama</b> (Address of Principal Executive Offices)	<b>35244</b> (Zip Code)
---	----------------------------

Registrant's telephone number, including area code: **(205) 444-4600**

**NOT APPLICABLE**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 9.01. Financial Statements and Exhibits.**

The following document extends the period of the SWO until November 17, 2008. It is being filed with this Form 8-K solely because it was inadvertently omitted from our Form 10-Q filed on October 31, 2008. The total contract amount remains unchanged (\$102,661,429). The contract completion date remains unchanged (December 31, 2010).

**Exhibit**

**Number**

**Description**

10.1	Amendment of Solicitation/Modification of Contract.
------	---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BioCryst Pharmaceuticals, Inc.**

Date: November 7, 2008

By: /s/ Michael A. Darwin

Name: Michael A. Darwin

Title: Vice President Finance

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
10.1	Amendment of Solicitation/Modification of Contract.